A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
Not Yet Recruiting
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to t... Read More
Gender:
ALL
Ages:
Between 65 years and 84 years
Trial Updated:
07/18/2025
Locations: Velocity Clinical Research, Omaha, Omaha, Nebraska
Conditions: Streptococcus Pneumoniae
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Completed
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/08/2025
Locations: Velocity Clinical Research Omaha, Omaha, Nebraska
Conditions: Pneumococcal Vaccines
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Completed
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.
Gender:
ALL
Ages:
Between 9 years and 11 years
Trial Updated:
06/30/2025
Locations: Midwest Children's Health Research Institute ( Site 0003), Lincoln, Nebraska
Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19)
A Study of BLB-201 RSV Vaccine in Infants and Children
Recruiting
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
06/30/2025
Locations: Velocity Clinical Research, Hastings, Hastings, Nebraska
Conditions: Respiratory Syncytial Virus Infections
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Completed
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/23/2025
Locations: Skyline Medical Center - PC - CCT - PPDS, Elkhorn, Nebraska +5 locations
Conditions: SARS-CoV-2, Influenza
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Completed
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Methodist Physicians Clinic - CCT Research, Fremont, Nebraska +5 locations
Conditions: Seasonal Influenza
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Velocity Clinical Research Norfolk- Site Number : 8400046, Norfolk, Nebraska +1 locations
Conditions: Influenza Immunization
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Active Not Recruiting
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/13/2025
Locations: Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400023, Lincoln, Nebraska +1 locations
Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
Active Not Recruiting
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/13/2025
Locations: GSK Investigational Site, Omaha, Nebraska
Conditions: Respiratory Syncytial Virus Infections
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
06/10/2025
Locations: Midwest Children's Health Research Institute- Site Number : 8400019, Lincoln, Nebraska +4 locations
Conditions: Pneumococcal Immunization
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Completed
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
Gender:
ALL
Ages:
Between 4 years and 6 years
Trial Updated:
06/05/2025
Locations: GSK Investigational Site, Lincoln, Nebraska +2 locations
Conditions: Measles; Mumps; Rubella; Chickenpox, Measles
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
Active Not Recruiting
The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the antibody response after one dose of the YF-VAX control vaccine in yellow fever naïve participants. The secondary objectives of the study are: * To describe the immune response to yellow fever in both vaccine groups before and after vYF or YF-VAX administration. * To descri... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/03/2025
Locations: Meridian Clinical Research- Site Number : 8400009, Omaha, Nebraska
Conditions: Yellow Fever, Healthy Volunteers